描述 USP22-IN-1 is a ubiquitin-specific peptidase 22 (USP22) inhibitor that can be used to treat proliferative diseases or cancer. 体外活性 USP22-IN-1(USP22i-S02)作为一种特异性的USP22抑制剂。(i)USP22i-S02(10 ug/mL)能够抑制Treg的抑制功能。[2] 体内活性 USP22-IN-1(USP22i-S02)(20...
2.DUB抑制剂| DUB Inhibitor 所有靶点(A-Z) · 所有产品(A-Z) · 化合物库. 热卖化合物库 ...
Furthermore, by inducing deubiquitination and inhibiting the degradation of PTEN, USP22 could induce cyclin-dependent kinase inhibitor 1A (CDKN1A, also symboled as p21) expression in pancreatic cancer. Besides, MDM2 proto-oncogene (MDM2) inhibitor enhanced the antipancreatic cancer effects of USP22 ...
Use of USP22-IN-1 USP22-IN-1 (compound S02) is a potent USP22 inhibitor. USP22-IN-1 decreases the expression of FOXP3, USP22 protein and Foxp3 mRNA levels. USP22-IN-1 enhanceds anti -tumor immunity[1]. Properties Spectrum
The proteasome-specific inhibitor MG132 rescued the HIF-1α protein from degradation in MYH9 knockdown cells (Fig. 3j; Supplementary Fig. 3h). Furthermore, MYH9 knockdown significantly enhanced polyubiquitination-induced HIF-1α degradation (Fig. 3k), while MYH9 overexpression significantly inhibited ub...
Notably, USP22 loss resulted in increased mTOR activity with the tumorigenic properties elicited by the loss of USP22 being reversible by mTOR inhibitor treatment in vitro and in vivo. Here, we demonstrate that USP22 can exert tumor-suppressive functions in CRC where its loss increases CRC ...
USP22 inhibitor might improve the efficacy of PD-L1/PD-1 antibodies by suppressing PD-L1 protein level. Combination of PD-L1/PD-1 blockade therapy with targeted therapy or chemotherapy have been proved to improve outcomes rather than monotherapy [56, 57]. Thus, combination of USP22 targeted ...
3.Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases and spring Shao-bo KE ,Hu QIU ,Jia-mei CHEN - 当代医学科学(英文) - 2018...
Investigating the role of a novel inhibitor of MOZ in B cell development and lymphoma This Masters study aimed to determine the effects of inhibition of the histone acetyltransferase MOZ (MYST3/KAT6A) on wild type and pre-leukaemic progenito... B Wang 被引量: 0发表: 2016年 加载更多来源...
Furthermore, a GSK3 inhibitor tideglusib sensitizes tumor xenograft to chemotherapy in mice via KDM1A down-regulation and improves survival. Our findings demonstrate that nuclear GSK3β and USP22-mediated KDM1A stabilization is essential for glioblastoma tumorigenesis. 展开 ...